Pluri Inc
Company Profile
Business description
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
Contact
MATAM Advanced Technology Park
Building No. 5
Haifa3508409
ISRT: +972 747108600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
142
Stocks News & Analysis
stocks
Oracle shares are up 87% in 2025. Is it a buy?
stocks
Is there a long-term buying opportunity in luxury stocks?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,137.80 | 14.90 | 0.16% |
CAC 40 | 7,904.82 | 74.71 | 0.95% |
DAX 40 | 23,681.34 | 154.29 | 0.66% |
Dow JONES (US) | 46,381.54 | 66.27 | 0.14% |
FTSE 100 | 9,241.76 | 15.08 | 0.16% |
HKSE | 26,159.12 | 185.02 | -0.70% |
NASDAQ | 22,788.98 | 157.50 | 0.70% |
Nikkei 225 | 45,493.66 | 447.85 | 0.99% |
NZX 50 Index | 13,136.54 | 5.00 | -0.04% |
S&P 500 | 6,693.75 | 29.39 | 0.44% |
S&P/ASX 200 | 8,845.90 | 14.30 | 0.16% |
SSE Composite Index | 3,821.83 | 6.74 | -0.18% |